Brett Chevalier

Brett Chevalier is a highly accomplished professional with a strong educational background in Biology, including a Postdoc in Stem Cells and Genomics from the Massachusetts Institute of Technology, a PhD in Molecular and Cellular Biology from the University of Washington, and a BA in Biology from Carleton College.

Throughout his career, Brett Chevalier has held key positions in renowned organizations, showcasing his expertise and leadership skills. Currently serving as a Venture Partner at Anterra Capital, Brett brings valuable insights and experience to the company's investments and strategic endeavors.

Prior to his role at Anterra Capital, Brett Chevalier has contributed significantly to the biotechnology industry. He has served as the Head Of Operations at CAMP4 Therapeutics, highlighting his proficiency in operational management and strategic planning.

Furthermore, Brett Chevalier has demonstrated his entrepreneurial spirit by founding and leading Corvium as the Chief Scientific Officer. His innovative approach and scientific acumen have been instrumental in the success of the company.

With a diverse professional background, Brett Chevalier has also worked as an Advisor at Corvium, a New Venture Associate at Flagship Ventures, a Research Scientist at Whitehead Institute, and a Senior Scientist (Systems Biology) at Agilent Technologies. These roles have honed his expertise in various aspects of biotechnology and research.

Brett Chevalier's extensive experience in both scientific research and business development positions him as a valuable asset in the biotechnology and venture capital sectors. His dedication to driving innovation and growth is evident in his past achievements and current role at Anterra Capital.